Diarapid CR: Russian short-acting insulin
Diabetes is one of the most common diseases in the world, and its treatment often requires constant administration of insulin. Insulin is a hormone synthesized by the pancreas that regulates blood glucose levels. One of the pharmacological agents for the treatment of diabetes is short-acting insulin Diarapid CR.
Diarapid CR is a short-acting insulin produced by the Russian pharmaceutical company Bryntsalov-A. This drug is used to lower blood glucose levels in patients with diabetes. It is in the pharmaceutical group of short-acting insulins, which means that it begins to act quickly after administration and has a short duration of action.
The international name is Diarapid CR - soluble insulin (human semi-synthetic). Insulin-Ferein CR is its synonym. The drug is produced in the form of an injection solution containing 100 IU/ml insulin.
The use of Diarapid PR should only be carried out under the supervision of a physician and in accordance with his recommendations. The dosage of the drug must be individualized and depends on many factors, including blood glucose levels, diet and physical activity of the patient.
Like any other medicine, Diarapid CR has its side effects. Some of these may include hypoglycemia (low blood glucose levels), allergic reactions, and lipodystrophy (changes in the shape of subcutaneous fat tissue at the injection site).
Overall, Diarapid CR is an effective pharmaceutical agent for treating diabetes and lowering blood glucose levels. However, before using it, be sure to consult your doctor and follow his recommendations.